This Saturday's March for Science is trying hard to be a nonpartisan event, but some may not see it that way. » Read More
The new plan to repeal and replace Obamacare is an attempt to bridge the gap between the House Freedom Caucus and moderates. » Read More
The new GOP health bill is just Obamacare with "limited waivers," says Jake Novak.
An analysis commissioned by pharmacy benefits managers revealed no correlation between drug prices and rebates.
The notorious pharma bro Shkreli denies claims he looted a drug company he founded to pay off hedge fund investors he allegedly defrauded.
Intuitive Surgical said it shipped 133 of its da Vinci surgical systems in the first quarter of 2017.
UnitedHealth is confident it will post better-than-expected growth for the full year, regardless of what happens with health reform.
In the last week, New Hampshire, Kentucky and Colorado have moved rate deadlines to June from April or May.
Cardinal Health says it expects earnings at the lower end of its forecast, causing a 12 percent tumble in shares.
The largest U.S. health insurer reported a 9.4 percent rise in quarterly revenue, driven by strength in its pharmacy benefit management business.
America’s most interesting policy fight is between the Republicans’ real and fake health policies, says Ezra Klein.
The news weighed on stocks in the hospital sector Monday, overshadowing some positive regulatory changes from the Trump administration.
Lilly says the FDA needed additional data to "characterize safety concerns across treatment arms."
Baxter's latest subpoena from the DoJ calls for an employee to produce documents related to shortages of products.
President Donald Trump has apparently not given up on repealing Obamacare.
Apple has a super-secretive initiative to develop sensors that can noninvasively and continuously monitor blood sugar levels.
Neurocrine says the FDA has approved Ingrezza, the only drug for treatment of adults with tardive dyskinesia.
Mylan said production at its Nashik site continues uninterrupted at this time.
Get the best of CNBC in your inbox